Drug Trial Radar · NCT00515892
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
Last checked: Nov 20, 2026Latest source record: Aug 14, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 2007
Primary completion
Not stated
Sponsor
- Lead sponsor
- Cambridge Antibody TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 14, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have Non-Hodgkin's lymphoma and do not respond to treatment.
Conditions
- Leukemia
- Non-Hodgkin's Lymphoma
- NHL
Interventions
Immunotoxin therapyDrug
CAT-8015 ImmunotoxinDrug
Biological therapyProcedure
Antibody TherapyProcedure
Monoclonal Antibody TherapyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate the maximum dose that can be safely administered to a patient; Characterize the toxicity profile of CAT-8015; Study the clinical pharmacology of CAT-8015; Observe anti-tumor activity, if any.
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Tower Hematology Oncology Medical Group
Beverly Hills, California · Recruiting
Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland · Recruiting
Klinika Hamtologii Uniwersytetu Medycznego (Medical University of Lodz)
Lodz, Poland · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.